利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.026 秒)

    Detection and treatment of breast disease
    1.
    发明授权
    Detection and treatment of breast disease 失效
    检测和治疗乳腺疾病

    公开(公告)号：US06306653B1

    公开(公告)日：2001-10-23

    申请号：US09146580

    申请日：1998-09-03

    申请人： Lawrence D. Papsidero ,  Lyn M. Dyster ,  Jana M. Frustaci

    发明人： Lawrence D. Papsidero ,  Lyn M. Dyster ,  Jana M. Frustaci

    IPC分类号： C12N512

    CPC分类号： C07K14/523 ,  A61K39/00 ,  Y10S530/832

    摘要： An isolated chemokine is disclosed. The isolated chemokine is expressed preferentially in breast tissue or can be detected in breast milk. It includes from about 100 to about 132 amino acids, has a deduced molecular weight of from about 10 to about 16 kDa, and has a deduced isoionic point of from about pH 10.1 to about pH 10.7. Antibodies and binding portions thereof recognizing the subject chemokine and peptides which include the antigenic portions of the subject chemokines are described. DNA molecules which encode the subject chemokines as well as nucleic acid molecules which, under stringent conditions, hybridize to nucleic acid molecules encoding the subject chemokines or to a complement thereof are also disclosed. The chemokines, peptides, antibodies and binding portions thereof, and nucleic acid molecules can be used to detect and treat breast disease, such as inflammations, infections, mastitis, benign cystitis, benign hyperplasias, cancer and other malignancies as well as other pathological states of the mammary gland.

    摘要翻译： 公开了一种分离的趋化因子。 分离的趋化因子优先在乳腺组织中表达或可以在母乳中检测到。 其包括约100至约132个氨基酸，具有约10至约16kDa的推测分子量，并且具有约pH 10.1至约pH 10.7的推导的等离子点。 描述了识别主题趋化因子的抗体及其结合部分和包括受试者趋化因子的抗原部分的肽。 还公开了编码主题趋化因子的DNA分子以及在严格条件下与编码主题趋化因子或其互补序列的核酸分子杂交的核酸分子。 趋化因子，肽，抗体及其结合部分和核酸分子可用于检测和治疗乳腺疾病，如炎症，感染，乳腺炎，良性膀胱炎，良性增生，癌症和其他恶性肿瘤以及其他病理状态 乳腺。

    Antibody catalysis of enantio- and diastereo-selective aldol reactions
    2.
    发明授权
    Antibody catalysis of enantio- and diastereo-selective aldol reactions 有权
    对映体和非对映选择性醛醇反应的抗体催化

    公开(公告)号：US06309881B2

    公开(公告)日：2001-10-30

    申请号：US09824279

    申请日：2001-04-02

    申请人： Carlos F. Barbas ,  Richard A. Lerner ,  Guofu Zhong

    发明人： Carlos F. Barbas ,  Richard A. Lerner ,  Guofu Zhong

    IPC分类号： C12N512

    CPC分类号： C07D417/06 ,  C07B2200/07 ,  C07D277/24 ,  C07D277/34 ,  C07D277/36 ,  C07D493/04 ,  C07K16/40 ,  C12N9/0002 ,  C12P7/26 ,  C12P17/16 ,  C12P17/18 ,  C12P41/002

    摘要： Nine efficient aldolase antibodies were generated using hapten 2. This hapten combines, in a single molecule, structural components employed for reactive immunization with structural components employed for forming a transition state analog of the aldol reaction. Characterization of two of these antibodies reveals that they are highly proficient (up to 1000-fold better than any other antibody catalyst) and enantioselective catalysts for aldol and retro-aldol reactions and exhibit enantio- and diastereo-selectivities opposite that of antibody 38C2.

    摘要翻译： 使用半抗原2产生九种有效的醛缩酶抗体。该半抗原在单个分子中结合用于反应性免疫的结构组分与用于形成醛醇反应的过渡态类似物的结构组分。 这些抗体中的两种的表征显示它们是非常熟练的（比任何其他抗体催化剂优于1000倍）和对映体选择性催化剂，用于醛醇醛和醛缩醇反应，并显示与抗体38C2相反的对映体和非对映体选择性。

    Antibodies, production method of the antibodies, hybridomas which produce the antibodies, production method of the hybridomas and antigen proteins recognized by the antibodies
    3.
    发明授权
    Antibodies, production method of the antibodies, hybridomas which produce the antibodies, production method of the hybridomas and antigen proteins recognized by the antibodies 有权
    抗体的制备方法，产生抗体的杂交瘤，抗体识别的杂交瘤的生产方法和抗原蛋白

    公开(公告)号：US06255107B1

    公开(公告)日：2001-07-03

    申请号：US09229932

    申请日：1999-01-13

    申请人： Makoto Kawai ,  Tadashi Okada ,  Fukiko Atsumi

    发明人： Makoto Kawai ,  Tadashi Okada ,  Fukiko Atsumi

    IPC分类号： C12N512

    CPC分类号： C07K14/705 ,  C07K16/28

    摘要： The invention is related to antibodies which specifically react with connective tissue type-human mast cells, a production method of the antibodies, hybridomas which produce the antibodies, a production method of the hybridomas and antigen proteins recognized by the antibodies. After cord blood cells were cultured in the presence of SCF and IL-6, they were further cocultured with primary culture of human skin fibroblasts, and connective tissue type-human mast cells were thus obtained. A rat was immunized using the cells, hybridomas were prepared and selected by an ordinary method, and novel monoclonal antibodies were harvested from the culture supernatant of the selected hybridomas. The monoclonal antibodies specifically reacted with connective tissue type-human mast cells.

    摘要翻译： 本发明涉及与结缔组织型 - 人肥大细胞特异性反应的抗体，抗体的制备方法，产生抗体的杂交瘤，由抗体识别的杂交瘤和抗原蛋白的制备方法。 在SCF和IL-6存在下培养脐带血细胞后，与人皮肤成纤维细胞的原代培养物进一步共培养，得到结缔组织型人类肥大细胞。 使用细胞免疫大鼠，通过常规方法制备杂交瘤并选择，并从所选择的杂交瘤的培养上清液中收获新的单克隆抗体。 单克隆抗体与结缔组织型 - 人类肥大细胞特异性反应。

    Antibodies to vascular endothelial cell growth factor
    4.
    发明授权
    Antibodies to vascular endothelial cell growth factor 失效
    血管内皮细胞生长因子的抗体

    公开(公告)号：US06582959B2

    公开(公告)日：2003-06-24

    申请号：US08950863

    申请日：1997-10-15

    申请人： Kyung Jin Kim

    发明人： Kyung Jin Kim

    IPC分类号： C12N512

    CPC分类号： C07K16/22 ,  A61K38/00 ,  A61K47/6425 ,  A61K47/6811 ,  A61K47/6843 ,  A61K2039/505 ,  C07K14/52 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

    摘要： The present invention provides monoclonal antibodies, and portions thereof, which are capable of specifically binding to human vascular endothelial cell growth factor (hVEGF) or hVEGF-related protein. The invention also provides hybridoma cell lines that produce such monoclonal antibodies. The monoclonal antibodies of the invention are useful as therapeutic agents, either by themselves or in conjunction with cytotoxic or other chemotherapeutic agents, to treat diseases that are characterized by excessive vascular endothelial cell proliferation. The monoclonal antibodies of the invention also are useful in diagnostic and analytical methods for determining the presence of hVEGF or hVEGF related-protein in a test sample.

    摘要翻译： 本发明提供能够特异性结合人血管内皮细胞生长因子（hVEGF）或hVEGF相关蛋白的单克隆抗体及其部分。 本发明还提供了产生这种单克隆抗体的杂交瘤细胞系。 本发明的单克隆抗体本身或与细胞毒性或其它化学治疗剂联用可用作治疗剂，以治疗以过量血管内皮细胞增殖为特征的疾病。 本发明的单克隆抗体也可用于测定样品中hVEGF或hVEGF相关蛋白的存在的诊断和分析方法。

    Converting diploidy to haploidy for genetic diagnosis
    6.
    发明授权
    Converting diploidy to haploidy for genetic diagnosis 失效
    将二倍体转化为单倍体用于遗传诊断

    公开(公告)号：US06399374B1

    公开(公告)日：2002-06-04

    申请号：US09461047

    申请日：1999-12-15

    申请人： Bert Vogelstein ,  Kenneth W. Kinzler ,  Hai Yan ,  Nicholas Papadopoulos

    发明人： Bert Vogelstein ,  Kenneth W. Kinzler ,  Hai Yan ,  Nicholas Papadopoulos

    IPC分类号： C12N512

    CPC分类号： C12N5/166 ,  C12Q1/6886 ,  C12Q2600/156

    摘要： Detection of mutations associated with hereditary diseases is complicated by the diploid nature of human cells. Mutations present in one allele are often masked by the wild-type sequence of the other allele. Individual alleles can be isolated from every chromosome within somatic cell hybrids generated from a single fusion. Nucleic acids from the hybrids can be analyzed for mutations in an unambiguous manner. This approach was used to detect two cancer-causing mutations that had previously defied genetic diagnosis. One of the families studied, Warthin Family G, was the first kindred with a hereditary colon cancer syndrome described in the biomedical literature.

    摘要翻译： 与遗传性疾病相关的突变的检测由于人类细胞的二倍体性质而复杂化。 存在于一个等位基因中的突变通常被其他等位基因的野生型序列掩蔽。 可以从单次融合产生的体细胞杂交体内的每个染色体分离个体等位基因。 来自杂种的核酸可以以明确的方式分析突变。 这种方法被用于检测先前不符合遗传诊断的两种致癌突变。 研究的家庭之一，Warthin Family G，是生物医学文献中描述的第一个遗传性结肠癌综合症患者。